Member Info for Moneymunch

Hi Yorkshireboy, a very interesting post.....in the agreement signed between Motif and Lamellar 1/5/19, it states that Motif will conduct an in vivo pre-clinical study evaluating iclaprim in combination with Lamellar's patented LAMELLASOME(TM) technology, which is a nebulised inhaler treatment , and so it's most interesting that in October 2019 ( Pre-Covid-19 ), Motif signed an agreement with WRAIR to conduct pre-clinical testing to evaluate novel combinations with iclaprim to improve safety and efficacy administered by a novel enhanced aerosol technology’....which sounds as if it could be Lemallar's Technology imho, and now the given timing of Lamellar's press release 8/4/20, in the midst of this global CV crisis , suggests that there could be a link to MOTIF as well as WRAIR imho.....Gl ;-)

https://www.ptcommunity.com/wire/lamellar-biomedical-launches-program-designed-prevent-severe-respiratory-effects-covid-19-using

A very interesting observation, courtsey of anslow on Advfn.

"I’ve noticed John Palmer from tamarack associates who’s responsible for finding a buyer is no longer advertising iclaprim for sale on his Linkedln profile, it was all there in black and white on Friday, big things happening here in the background."

Not too sure what the upside would be, but any potential treatment for severe lung disorders in Covid patients that could go straight into patient trials , would see the sp rise exponentially imho, and if positive results were confirmed, then the sky's the limit.......isn't NYCT up over 8,500% since last year and that's just on the back of testing kits for Covid-19 and so i'm sure an actual treatment as described by Lamellar would be even bigger again. Gl ;-)

If Iclaprim is the main compound in Lamellar's LAMELLASOME™ nebulised formulation treatment believed to have inherent attributes that are extremely well suited to be a potential approach to preventing the onset of the serious respiratory symptoms seen in COVID-19 patients, then presumably because Iclaprim has already been cleared in Phase 11 patient trials, then Lamellar's technology and formulation could go straight into CV patient trials. This would be highly significant and make Lamellar the most likely RTO target and transformational for all invested, with the prospect of Lamellar's inhaler technology reaching CV patients immediately , and then potentially scaled up for commercialisation on positive trials, and if this is the case then this would be absolutely huge and maybe the multi-bags of all multi-bags from current rockbottom sp. Gla holders and fingers firmly crossed!!! ;-)

Interesting points made by Doc Holiday, in that Motif's main investor Hercules Capital put about $20m into Icaprim's development ,most of which was transferred into share warrants at 0.42p which represents 29% of the company and so they will be keen to recoup their investment at all costs. Icaprim showed strong positive phase 11 trial data for bronchial pneumonia etc, and although they've had no luck in selling the program to date, all of a sudden because of the CV crisis, Icaprim's phase 11 trial data could now be of great interest from those involved in finding treatments for CV patients who are suffering from lung problems, which is hopefully backed up by Lamellar's studies, there's also a great chance that if a Covid related developer wants to gain access to the markets quickly to get their products to market, then the chance of RTO, is very high. Gla holders, all should be revealed this coming week. :-)

Doc Holdiday soundcloud......... 15m 40ish seconds into into recording, most definitely worth a listen and very encouraging imho Gla ;-)

https://soundcloud.com/doc-h-4/easter-weekend

Doc Holiday
Easter Weekend ?? #INCE #ORPH #FXPO #NCYT #IHC #RRE #CLG #TILS #MTFB #PFC #PDL #RGM #WSG #LBE

https://soundcloud.com/doc-h-4/easter-weekend

Iclaprim has been granted U.S. orphan drug designation for Staphylococcus aureus pneumonia in patients with Cystic Fibrosis (CF)

Lamellar's LAMELLASOME(TM) candidate LMS-611, which has mucokinetic (mucus clearing) properties, has demonstrated antibiotic potentiation (the enhancement of certain properties of antibiotics) and has European orphan drug designation for CF.

The companies believe that, based on pre-clinical data with the two individual components, the combination could be a promising potential treatment for lung infections in patients with CF.

Lamellar signed the agreement with Motif 1st May 2019 for the Evaluation of Iclaprim in Combination with LMS-611 for Cystic Fibrosis Lung Infections, this was several months after the FDA had rejected Iclaprim's NDA on toxicity concerns and had requested another costly Phase 111 trial, the the New Drug Application (NDA) for iclaprim was for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and the drug was also administered intravenously, whereas Lamellasome's Technology is a nebulised treatment and pre-clinical studies are focused on lung infections, where the formulations are administered through inhalation, are now thought to be potentially highly effective in treating lung disorders in Covid-19 patients.

Ps could all be pie in the sky, but very interesting and maybe more than coincidence that the sp here rose so dramatically a day or two after Lamellar's promising press release. Gl ;-)

8/4/20

Lamellar Biomedical Launches Program Designed to Prevent the Severe Respiratory Effects of COVID-19, Using its Unique LAMELLASOME™ Technology

....................

A LAMELLASOME™ nebulised treatment used at the early stages of COVID-19, in hospital or the community, could reduce the damaging and often fatal inflammatory response known as Acute Respiratory Distress Syndrome (ARDS) seen in patients. This early intervention has the potential to inhibit fibroproliferative changes during ARDS, markedly reducing severity, mortality and lowering the significant burden placed on the healthcare system.

The time between onset of symptoms of SARS-CoV2 infection and progression to more severe clinical manifestations of COVID-19 such as viral pneumonia and ARDS, is thought to be between 5 – 8 days. Inhaled LAMELLASOME™ treatment administered during this period has the potential to halt or reduce the severity of the disease progression of COVID-19 patients to requiring scarce critical care resource.

Lamellar has strong pre-clinical evidence of inhaled LAMELLASOME™'s protective nature. In a large animal in-vivo model of radiation-induced lung injury, designed to replicate the pathology found in the injured lung, which is representative of COVID-19 patient pathology, inhaled LAMELLASOME™ treatment protected lung cells and tissues from injury, pneumonitis and fibroproliferation/fibrosis at the alveolar/capillary membrane.

Dr Duncan Moore, Chairman of Lamellar, said: "In the past few weeks we have seen the terrible consequences COVID-19 can have on the respiratory function, particularly on vulnerable patient populations. We believe that that the inherent attributes of LAMELLASOME™ are extremely well suited to be a potential approach to preventing the onset of the serious respiratory symptoms seen in COVID-19 patients. Lamellar is focused on treating complex lung disorders and we believe that our Lamellasome formulations could make an important difference to patients and healthcare providers globally."

Dr Nik Hirani, Reader in Respiratory Medicine and Associate Medical Director in Lothian and Former chair of NICE Thoracic Interstitial Lung Disease guideline committee, said: "Lamellar has very convincing data demonstrating strong in-vivo efficacy for Lamellasome formulations in a model relevant to pneumonitis, lung injury and ARDS. I have been following the development of LAMELLASOME™ technology and its development as a respiratory therapeutic over the past few years, and I believe it has real potential to manage the inflammatory respiratory symptoms seen in patients infected with SARS-CoV2."

https://www.ptcommunity.com/wire/lamellar-biomedical-launches-program-designed-prevent-severe-respiratory-effects-covid-19-using

3 positive scenario's for the rise in sp.....news of a RTO, news of sale of Assets ( iclaprim ) or confirmation that Lamellasome formulations, that are believed to be extremely well suited to be a potential approach to preventing the onset of the serious respiratory symptoms seen in COVID-19 patients, does infact inlude Iclaprim in combination. Gla ;-)

18/3/20

The Company's Directors remain focused on sourcing an appropriate reverse takeover candidate for Motif Bio and this search continues.

1/5/19

Motif Bio Signs Agreement with Lamellar Biomedical

Evaluation of Iclaprim in Combination with LMS-611 for Cystic Fibrosis Lung Infections

Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has signed an agreement with Lamellar Biomedical Limited (Lamellar) under which Motif Bio will conduct an in vivo pre-clinical study evaluating iclaprim in combination with Lamellar's patented LAMELLASOME(TM) technology.

Iclaprim has been granted U.S. orphan drug designation for Staphylococcus aureus pneumonia in patients with Cystic Fibrosis (CF). Lamellar's LAMELLASOME(TM) candidate LMS-611, which has mucokinetic (mucus clearing) properties, has demonstrated antibiotic potentiation (the enhancement of certain properties of antibiotics) and has European orphan drug designation for CF.

The companies believe that, based on pre-clinical data with the two individual components, the combination could be a promising potential treatment for lung infections in patients with CF.

Dr. Graham Lumsden, Chief Executive Officer of Motif Bio, said: "We have been looking for a way to optimise the development of iclaprim in patients with CF. We are excited about the preliminary data we have seen with Lamellar's technology and look forward to evaluating it in combination with iclaprim."

Dr. Alex McLean, Chief Executive Officer of Lamellar Biomedical, said: "CF is a key area of interest for Lamellar. We are delighted to announce this partnership with Motif Bio, which will evaluate the antibiotic potentiation properties of our LAMELLASOME(TM) technology in combination with iclaprim. This collaboration augments our own work in this orphan indication, which is focused on a novel nucleic acid-based therapeutic, as we strive to develop a range of highly effective treatment options for patients with CF."

6/6/19

"We continue to believe that iclaprim has the potential to be an important new treatment option for hospitalised patients with ABSSSI and potentially also in patients with hospital-acquired bacterial pneumonia, including ventilator-associated bacterial pneumonia. In addition, we are exploring the use of iclaprim in other disease areas, including orphan indications such as Staphylococcus aureus lung infections in patients with cystic fibrosis and in ophthalmology, as evidenced by recently announced collaborative agreements.

i don't think they have started the sales process, it's provision for an additional $20m if and when needed imho.....they've just raised $10m and so enough cash going forward for now. Gl ;-)

Rather than any immediate additional fund raise, it looks like the Prospectus Supplement dated 10/4/20 is provision for a further $20m, if and when needed, on top of the $10m recently raised which will be used to advance all products in development??? Gl ;-)

Lamellar Biomedical says lung treatment could save lives of Covid-19 patients

Lanarkshire life sciences firm's drug can halt inflammation at early stage of disease

8 APR 2020

Lanarkshire firm Lamellar Biomedical says one of its treatments could help save lives by halting progression of lung damage in Covid-19 patients.

The company has pre-clinical evidence that Lamellasome can protect lung cells and tissue if inhaled within five to eight days of symptoms of respiratory lung disease.

It says early intervention can prevent the Acute Respiratory Distress Syndrome (ARDS) seen in coronavirus patients.

Lamellar chairman Dr Duncan Moore said: “In the past few weeks we have seen the terrible consequences Covid-19 can have on the respiratory function, particularly on vulnerable patient populations.

"We believe that that the inherent attributes of Lamellasone are extremely well suited to be a potential approach to preventing the onset of the serious respiratory symptoms seen in Covid-19 patients.

"Lamellar is focused on treating complex lung disorders and we believe that our Lamellasome formulations could make an important difference to patients and healthcare providers globally.”

Lamellar, based at Eurocentral near Motherwell, was founded in 2007, with the aim of developing an early-stage treatment for the lung disease Idiopathic Pulmonary Fibrosis but it has applications for other lung conditions.
138307337985

Lamellosome can be used to reduce inflammation or as a vehicle to deliver other drugs.

Investors include Invesco, Scottish Enterprise, Barwell Plc, TRI Capital and it works in partnership with the universities of Edinburgh and Strathclyde.

Dr Nik Hirani, Reader in Respiratory Medicine at the University of Edinburgh, said: “Lamellar has very convincing data demonstrating strong in-vivo efficacy for Lamellasome formulations in a model relevant to pneumonitis, lung injury and ARDS. I have been following the development of Lamellosome technology and its development as a respiratory therapeutic over the past few years, and I believe it has real potential to manage the inflammatory respiratory symptoms seen in patients infected with SARS-CoV2.”

“We hope to activate this across all of our networks, and all institutions that are not already participating in one of the various phase III randomized trials that are out there for tocilizumab, or any other IL-6-related agent.”

NCI to distribute IL-6 inhibitor for cancer patients with COVID-19 lung inflammation

By Matthew Bin Han Ong



This story is part of The Cancer Letter’s ongoing coverage of COVID-19’s impact on oncology. A full directory of our coverage is available here.



NCI is finalizing plans to use its clinical trials networks to administer a compassionate use protocol for distribution of tocilizumab, a drug that blocks the inflammatory protein IL-6.

Tocilizumab, an immunosuppressive agent also known by its brand name Actemra, is sponsored by Genentech. Under NCI’s protocol, the drug will be made available to cancer patients at institutions that are not participating in Genentech’s phase III trial of the drug.

The IL-6 inhibitor was approved by FDA for rheumatology indications in 2011, and has been used for mitigation of cytokine release syndrome caused by CAR T-cell therapy.

According to Genentech, the federal government has obtained 10,000 vials of tocilizumab for the U.S. Strategic National Stockpile “for potential future use at the direction of the HHS.”

It is one of three drugs—the other two being sarilumab and siltuximab—that are now being rushed into late-stage clinical trials for assessment of efficacy in treatment of acute respiratory distress syndrome caused by immune response to SARS-CoV-2 infection (The Cancer Letter, March 27, 2020).

“We are going to, in concert with Genentech, run a treatment referral trial for the Genentech Roche IL-6 receptor antibody for COVID-related ARDS,” James Doroshow, deputy director for clinical and translational research at NCI, said April 9 in an emergency virtual joint meeting of the NCI Board of Scientific Advisors and the National Cancer Advisory Board.

“We wrote a trial, I would like to say—just like in the old days—in four days, a trial was put up. It’s been reviewed by Genentech Roche,” said Doroshow, who is also director of NCI’s Division of Cancer Treatment and Diagnosis and head of the Oxidative Signaling and Molecular Therapeutics Group of NCI’s Developmental Therapeutics Branch. “I hope to be able to have a final version of this to the central IRB very quickly.”

NCI’s protocol for tocilizumab is designed to rapidly make the drug available to cancer patients, who face a particularly high fatality risk from severe complications stemming from COVID-19.

“Why do this? Well, because we know that there are multiple randomized trials and multiple institutional trials,” Doroshow said. “There are some folks who simply can’t afford to get this drug, and we wanted to have a very broadly eligible study, eligible even for patients very young in age, which is not addressed by most of the trials that are out there, to try to see whether we can move the needle in terms of decreasing ICU time, ventilator time, time in the hospital.

“We will collect some clinical data. It’ll be a modest set of data,” Doroshow said. “There will be blood obtained for biomarker evaluation.

Lol , just digging around to put some potential substance behind the rumour, could be a load of tosh and we'll come crashing down on Tuesday, but yesterday's rise was impressive and sustained with no real sell off with buys coming in thick and fast towards close , which obviously is very encouraging that good news could be on it's way , especially that no speeding ticket appeared after rusing 100%, 200% and 300%......Boom or Bust coming??? Fingers firmly crossed that its BOOM!!! Gl :')

In summary, issuers must notify without delay major new developments that may affect their business if the development may lead to a substantial share price movement. Issuers must also notify without delay information concerning a change in financial condition, performance or expectation of performance if the change would be likely to lead to a substantial share price movement.

There are exclusions from these notification requirements relating to impending developments and matters in the course of negotiation, such as acquisitions or disposals. There is also a power for the UKLA to grant a dispensation from these requirements where the disclosure to the public of information might prejudice the company's legitimate interests 

Fingers crossed liquid1, we know they're looking for a RTO and so who knows, and if it is an Isreali Bio developing treatment/testing for Covid 19, then this will go Big time, and so hopefully we might have an idea come Tuesday. Gl :-)

Tonnacombe....i have a trading account with Interactive Investor and it took me about 20 seconds to register for overseas trading which near enough includes every exchange including Nasdaq, and i imagine it will be the same simple and quick process for every other UK on-line broker. Gl ;-)

bigboots - 09 Apr 2020 - 13:16:23 - 4385 of 4432

Talk of a small non listed Pharma/Bio company reversing into MOTIF to evaluate a targeting test and cure for COVID 19

They are at an advanced stage with both - They are Israeli

..........

Maybe some potential substance to bigboots post on Advfn!!!??? ;-)

30 Israeli medical innovations to fight coronavirus

Whether it’s in diagnostics, treatment or care management, Israel's innovators are busy inventing and adapting technologies to ease the coronavirus burden on the world.

March 30, 2020

https://www.israel21c.org/30-israeli-medical-tech-solutions-to-help-fight-coronavirus/

The delisting was planned for Q2 2020, although every chance this could be delayed due to the impact of CV crisis, although it really isn't an issue as all TILS Aim shares would be exchanged for Nasdaq shares wjhich are easily traded on most UK on-line brokers that the majority of us use.

Here's a recent example of a dual listing, Summit's sp almost doubled on Nasdaq after delisting from Aim in February, all SUMM's Aim shareholders shares were converted/transferred to Nasdaq shares, Bring it on!!!, Gla :-)

February 11, 2020 05:00 ET | Source: Summit Therapeutics plc

Summit Therapeutics plc
(“Summit Therapeutics” or the “Company”)

AIM Delisting Reminder

Oxford, UK, and Cambridge, MA, US, 11 February 2020 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, issues a reminder that, as previously announced and pursuant to AIM Rule 41, the Company’s ordinary shares of one penny nominal value (“Ordinary Shares”) will cease to be admitted to trading on AIM at 7.00 am on 24 February 2020. Accordingly, the final day of trading on AIM of the Company’s Ordinary Shares will be 21 February 2020.

The Company’s American Depositary Shares (“ADSs”) will remain listed on the Nasdaq Global Market and all public trading of shares in the Company after that date will take place on that exchange; one ADS is represented by five Ordinary Shares. Thereafter, Ordinary Shares will continue to be capable of being held and transferred in certificated form, but there will be no public market in the UK on which the shareholders of the Company will be able to trade Ordinary Shares.

Shareholder are able to convert Ordinary Shares into ADSs and by doing, are able to trade such ADSs on Nasdaq. Further information can be found on the Company’s website at https://www.summitplc.com/investors/investor-centre/ under the heading “AIM Delisting FAQs”.